5-(5-fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide,
SU 011248,
SU 11248,
SU-011248,
SU-11248,
SU011248,
SU11248,
sunitinib,
sunitinib malate,
Sutent,
Sunitinib malate,
341031-54-7,
Sutent,
Sunitinib malate [USAN],
UNII-LVX8N1UT73,
SU011248 L-malate salt,
SU 011248,
PHA-290940AD,
LVX8N1UT73,
SU010398,
SU011248,
SUNITINIB MALEATE,
SU-11248,
MFCD08282795,
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate,
SU 11248,
(Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (S)-2-hydroxysuccinate,
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1),
AK544273,
PDGF TK antagonist,
Sutent (TN),
AC1O5CMQ,
Sutent (TN) (Pfizer),
Sunitinib Malate (Sutent),
(-)-malic acid; sunitinib,
CHEMBL1567,
SU-11248 L-malate salt,
Sunitinib malate (JAN/USAN),
SU-011248 L-malate salt,
SCHEMBL1258610,
SCHEMBL1772213,
C26H33FN4O7,
AOB5508,
QCR-103,
LBWFXVZLPYTWQI-IPOVEDGCSA-N,
PNU-290940AD,
HMS3261H09,
N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-2-hydroxybutanedioic acid (1:1) salt,
Sunitinib malate, >=98% (HPLC),
Tox21_500514,
AN-777,
NSC736511,
s1042,
SU-11248J,
AKOS005145765,
AKOS025149097,
Sunitinib Malate (Sunitinib L-Malate),
API0024508,
CCG-221818,
CS-0177,
KS-5023,
NSC-736511,
RL03260,
NCGC00261199-01,
AT-15587,
Butanedioic acid, 2-hydroxy-, (2S)-, compd. with N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1),
HY-10255,
SU112248,
AB0020988,
LS-186078,
SU-010398,
TL8002546,
AM20090634,
FT-0083555,
SW219407-1,
V2095,
D06402,
X-1524,
031S547,
J-019449,
Sunitinib Malate|341031-54-7|Sutent|SU-11248|Sunitinib,
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1),
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1),
1H-Pyrrole-3-carboxamide,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1),
1H-Pyrrole-3-carboxamide,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, malate salt,
Butanedioic acid, (2S)-, compd. with N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1),
Butanedioic acid, (2S)-, compd. with N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1) (CA INDEX NAME),
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; (2S)-2-hydroxybutanedioic acid,
N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidine)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-2-hydroxybutanedioate salt,
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide;(2S)-2-hydroxybutanedioic acid,
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-indolin-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; (2S)-2-hydroxybutanedioic acid,
Sunitinib,
ACN-031544,
CID6456015,
CS-O-11751,
Su-011248,
Sunitinib malate, 98% - 10MG 10mg,
SU-12662,
C22-H27-F-N4-O2.C4-H6-O5,
A10880,
N-(2- -5-( - -2,4-dimethyl-1H-pyrrole-3-carboxamide -hydroxybutanedioate,